(Reuters) -Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.

It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...

Evidation has also been working with Eli Lilly's rival in diabetes, Sanofi, in a partnership along similar lines. Garmin steps into medical wearables Tech-giant Garmin is stepping into the medical ...

In Fountain Square, it was hard hard to miss the proverbial red carpet the City of Indianapolis rolled out for WWE fans visiting central Indiana for Saturday night’s Royal Rumble at Lucas Oil ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.